Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Prostate Cancer Patients
DRUG: Repaglinide, Bupropion and SHR3680
Peak Plasma Concentration(Cmax), Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for Repaglinide and Bupropion, Day1 and Day21|Area under the plasma concentration versus time curve(AUC0-t), Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for Repaglinide and Bupropion, Day1 and Day21
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion